Organic Active Ingredients TRIZ Cases

Modular N-glycan arrays immobilized on aluminum oxide substrates enable precise binding profiling of glycan-binding molecules.

Amino acid derivatives inhibit NF-kB activation, offering safer anti-inflammatory therapy with fewer side effects than corticosteroids.

UCP2 inhibitors drive metabolic reprogramming in CD8+ T cells to boost immune responses.

Modified oligonucleotides bind to alpha-synuclein genes to inhibit expression, overcoming early loss of effect in non-viral delivery.

Induced pluripotent stem cells differentiate into neural stem cells expressing CD-UPRT genes to deliver suicide gene therapy.

Calcium silicate supports nicotine to reduce oxidative degradation and manufacturing costs while enabling a universal formulation.

Modular inhibitor design combines peptide backbones with carbohydrate warheads to boost therapeutic efficacy while minimizing off-target effects.

Optimized aminoglycoside dosing induces premature stop codon read-through for progranulin restoration while mitigating mitochondrial translation impairment.

Local quality and parameter changes optimize oxazole derivatives to resolve potency and bioavailability trade-offs in Syk inhibition.

Nitrogen-based fertilizers act as precursors to increase glucosamine content in plant materials, reducing raw material requirements for industrial production.

Culturing mesenchymal cells with TPO derivatives promotes c-MPL receptor expression on the cell surface.

Pyrimidine analogues achieve selective TYK2 inhibition over JAK2 by exploiting distinct binding pocket features.

Deuterium oxide labeling and mass spectrometry analysis measure gluconeogenesis rates to overcome the complexity of traditional biomarker measurements.

Nonsymmetric 1,1'-biphenyl derivatives replace costly antibodies by binding PD-L1 to induce dimerization, reducing adverse immune effects.

Segmented polymeric linkers attach multiple therapeutic agents to antibody targets via cleavable bonds.

Formula I compounds inhibit dihydroorotate dehydrogenase to induce cellular differentiation and apoptosis in acute myelogenous leukemia.

Administering an Nrf2 inhibitor suppresses antioxidant enzymes, restoring oxidative stress sensitivity in resistant lung and prostate cancers.

Down-regulating p53 activity with specific compounds restores lymphatic vessel development and drainage function.

Repurposing eltrombopag inhibits Cryptococcus growth and virulence while reducing nephrotoxicity risks associated with traditional antifungals.

Segmented synthesis of benzothiazepines increases colonic bile acid concentrations to enhance GLP-1 secretion, reducing weight gain risks.

Quinoxaline derivatives antagonize A2A and A2B receptors to overcome immunosuppression in cancer treatment.

Structural optimization of cyclopropyl urea compounds resolves the trade-off between reducing inflammation and promoting tissue repair via receptor activation.

Sodium stearyl fumarate lubricates lacosamide tablets via dry granulation to enhance flowability and maintain strength.

Irradiating riboflavin-treated wounds with UVA light enhances tissue bonding strength while minimizing oxidative stress.

Selective binding removes larger contaminating clusters from mixtures, yielding high purity atomic quantum clusters for therapeutic use.

Novel SMO modulator compounds inhibit Hedgehog signaling through targeted molecular structures.

Nitazoxanide treats cholestatic diseases by reducing circulating bile acid levels and α-SMA expression.

Combining urinary basifying agents with saponin crystallization inhibitors prevents uric acid oversaturation while avoiding calcium phosphate lithiasis risks.

A senolytic prodrug incorporates a galactosyl moiety to mask cytotoxic activity until enzymatic cleavage releases the active agent.

Elaeocarpus petiolatus extract inhibits Resistin-CAP1 binding to reduce inflammatory responses in cardiovascular systems.

Merges CDK4 inhibition with antiandrogen therapy to overcome resistance in castration-resistant prostate cancer.

A computer-implemented dosage calculator determines rivaroxaban administration levels using a plasma level prediction model derived from patient data.

Flavored oral liquid suspension of antineoplastic alkylating agents masks bitter taste and improves stability for better patient compliance.

Syndecan-4 identifies resistant cancer stem cells, allowing siRNA or antibody treatment to eliminate them while sparing normal tissue.

A urea compound acts as a potent FPRL1 agonist to suppress neutrophilic infiltration.

Aziridinyl-epothilone analogs conjugated with folate-binding moieties selectively target cancer cells overexpressing folate receptors.

Segmenting the synthesis using N-benzyl protected histidine intermediaries resolves low yield and high cost bottlenecks in ergothioneine manufacturing.

RNA interference agents silence EPAS1 mRNA to reduce protein levels and address pathological over-expression.

Segmented intravenous tramadol administration balances rapid pain relief against seizure risks by maintaining safe plasma concentrations.

Apoaequorin and vitamin D compositions stabilize physiological calcium levels through synergistic binding and absorption mechanisms.

A hemocompatible polymer sorbent cartridge removes inflammatory mediators from patient blood via extracorporeal circulation.

Wrapping material uses synthetic cooling compounds to boost chill intensity while avoiding the flavor contamination of natural menthol.

An interference fit joins tubular sections at room temperature, preventing thermal degradation of the encapsulated medication.

A novel imidazo isoindole derivative inhibits indoleamine 2,3-dioxygenase activity through specific structural modifications.

Pyrrolopyridine derivatives activate PPAR delta and gamma receptors to lower triglycerides while avoiding peripheral insulin resistance.

Substituted triazole compounds inhibit stearoyl-CoA desaturase to manage dyslipidemia and reduce amyloid plaque formation.

Cyclic disulfide moieties mask negative charges on phosphate groups, enabling cell membrane penetration while minimizing toxicity from cleavage byproducts.

CD47-engineered exosomes deliver siRNA to suppress oncogenic Kras, reducing tumor burden while minimizing cytotoxic effects.

Combining pemirolast and ramatroban reduces inflammatory mediator release and cell proliferation while avoiding statin side effects.

Catechol-modified dopaminergic agonists inhibit alpha-synuclein aggregation while reducing oxidative stress from non-specific receptor binding.

Merging aflibercept with FOLFIRI overcomes limited survival rates by improving progression-free and overall survival metrics.

Vibegron treats nocturnal pollakiuria by reducing nighttime urination frequency without the adverse reactions seen with desmopressin.

Tetrahydrobiopterin supplementation restores gastric emptying speed by enhancing enzyme activity in diabetic patients.

Palmitoyltransferase inhibitors target DHHC9 enzymes to prevent viral membrane association and syncytia formation.

Antisense phosphorodiamidate morpholino oligomers suppress SARS-CoV-2 replication by binding complementary mRNA sequences, reducing viral protein production.

Embedding liposomes in a hydrogel matrix maintains drug concentration and reduces administration frequency.

Hydrophobic monomers self-assemble into fibrillar aggregates that disrupt microtubule growth in cancer cells while sparing neuronal tissue.

Nanostructured biomaterials accelerate chondrocyte proliferation to repair cartilage defects without inflammatory reactions.

Biotechnological chondroitin sulfate with controlled molecular weight and specific sulfation profile enhances bioavailability.

Adjusting the pH range to 2-5 with fumaric acid stabilizes compound (I) against decomposition while maintaining adequate solubility for therapeutic efficacy.

C-16 substituted chenodeoxycholic acid analogues enhance TGR5 potency and selectivity to treat metabolic diseases.

Merging CDK4/6 and PI3K inhibitors overcomes treatment resistance while enhancing therapeutic effectiveness against solid tumors.

C5-C6-carbocyclic fused iminothiadiazine dioxide compounds inhibit BACE enzymes to block amyloid-beta production.

Topical naratriptan treats erythematotelangiectatic rosacea by reducing neurogenic inflammation and preventing rebound effects.

Covalent bonding of ticagrelor via a self-assembled monolayer prevents washout while eliminating systemic bleeding risks.

Fused aromatic imide polymer chains anchor pigments to prevent agglomeration and settling, maintaining stable dispersion under high temperatures.

Racemic ornidazole eradicating Burkholderia mallei biofilms overcomes antibiotic resistance and high minimum inhibitory concentrations.

Heating ketone solvates yields stable Form α′, preventing degradation during pharmaceutical manufacturing.

Crystal form A of the c-MET inhibitor improves metabolic stability and half-life by reducing clearance rates compared to tepotinib.

Small-molecule inhibitors target cGAS to resolve limited treatment effectiveness and unknown mechanisms in systemic lupus erythematosus by blocking DNA binding.

Novel mepicides inhibit the Dxr enzyme to overcome bioavailability limits and drug resistance in malaria and tuberculosis treatments.

Targeting SMOC2 via siRNA silences the protein driver of fibroblast transition, addressing insufficient efficacy in current kidney fibrosis therapies.

Ophthalmic formulation combines hydrocortisone with a lacrimal substitute to enhance viscosity and stability on the ocular surface.

A benzamide compound selectively inhibits Akt3 kinase activity to modulate regulatory T cell function.

A water-soluble hyaluronic acid gel uses polyhydric alcohol and controlled organic solvent to maintain natural material properties.

Pyrimidine derivatives target ALK, FAK, ZAP-70, and IGF-1R kinases simultaneously, addressing inadequate single-target cancer therapies.

Polymorph B crystallization prevents rapid oxidation and extends shelf life for phenylketonuria treatments without requiring expensive cold chain storage.

Modular pyrazino naphthyridine scaffolds overcome drug resistance in cancer cells by delivering potent CK2 inhibition and broad antitumor efficacy.

Replacing chemical synthesis with enzymatic catalysis, the modified host achieves stereochemical control and substrate flexibility for novel drug leads.

Mitoketoscins bind to ACAT1/2 and OXCT1/2 enzymes to inhibit mitochondrial ATP production in cancer cells.

Pyrimidine dione compounds stabilize beta cardiac myosin conformation, reducing left ventricular outflow obstruction in hypertrophic cardiomyopathy.

Phenoxyethylamine derivatives balance aberrant cortico-striato-thalamic network functioning by simultaneously targeting dopamine D2, D1, and NMDA receptors.

ANGPTL7 inhibitors reduce intraocular pressure and prevent vision loss in glaucoma patients by adjusting doses according to specific genetic risk markers.

Fluorinated isoxazoline compounds extend half-life to control ectoparasites for months, reducing treatment frequency and improving animal health management.

Administering methionine sulfoximine inhibits glutamine synthetase, reducing cytokine production and preventing liver cell death in acute liver failure.

Targeting Factor 12 reduces bradykinin production and vascular permeability to treat hereditary angioedema.

Morpholino pyrimidine derivatives resolve potency and selectivity trade-offs by targeting Class Ia and Ib kinases to disrupt cell proliferation pathways.

Antisense oligomers facilitate removal of retained introns from pre-mRNAs, restoring functional protein levels in genetic disorders.

Specific quinazoline derivatives inhibit aberrant nuclease activities to treat cancers where existing treatments fail to modulate enzyme function.

Polysubstituted pyrimidopyrrole compounds overcome Crizotinib resistance in non-small cell lung cancer by targeting ALK and c-Met pathways.